# LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

> **NCT07312422** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang Provincial People's Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Pancreatic Cancer
- PD-L1
- PD-1 Inhibitor
- LDRT
- Proterizumab

## Interventions

- **RADIATION:** Low-dose Radiotherapy
- **BIOLOGICAL:** Pucotenlimab
- **DRUG:** AG regimen
- **DRUG:** FOLFIRINOX regimen

## Key facts

- **NCT ID:** NCT07312422
- **Lead sponsor:** Zhejiang Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07312422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07312422, "LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07312422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*